Drug Trial Radar · NCT03886662
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Apr 2019
Primary completion
May 2021
Study completion Jul 2021
Sponsor
- Lead sponsor
- Lixte Biotechnology Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and efficacy (benefits) of an investigational drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been administered to patients with various solid tumors. In this study, LB-100 will be administered as an intravenous infusion over 120 minutes. This study will be conducted in 2 phases. In phase Ib, escalating doses of LB-100 will be administered to patients to study the safety and to determine a safe dose of LB-100. In phase 2, patients will be administered LB-100 at the dose that was found to be safe in phase Ib. The efficacy (benefits) and safety of LB-100 will be determined in this phase of the study.
Conditions
- Myelodysplastic Syndromes
Interventions
LB-100Drug
Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes. Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For Phase Ib - Number of patients with adverse events related to the study treatment as a measure of safety and tolerability of LB-100 study drugTime frame: From the first dose of the study drug to 30-days following last dose of the study drug
- For Phase 2 - Best overall response rate of patients to the study treatment as a measure of efficacy of LB-100 study drugTime frame: At screening and then at the end of Cycle 3 and Cycle 6. (Each cycle is 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.